The supplement allows the company to expand patient enrollment in the REMIND investigational device exemption (IDE) study. MMI can now increase enrollment beyond the initial five-patient cohort to a full early feasibility study population of 15 patients. The company received the FDA’s go-ahead to conduct the study in November 2025.
REMIND evaluates microsurgical intervention for neurodegenerative disease, including Alzheimer’s disease. The first-of-its-kind trial evaluates the safety and feasibility of the Symani surgical robot in microsurgery in the region of the neck.
Symani allows surgeons to connect lymphatic vessels to nearby veins. By connecting the vessels, smaller than several strands of hair, the procedure helps reroute fluid and relieve swelling. Medical Microinstruments touts Symani as the only microsurgical robot approved for commercial use. It won FDA de novo clearance for Symani, covering soft tissue manipulation to perform microsurgery, in April 2024.
Symani provides advanced solutions for a range of open surgeries. That includes post-mastectomy breast cancer reconstruction, extremity reconstruction using free tissue transfer and lymphatic system repair. The NanoWrist instruments help to access and suture small, delicate anatomies. Additionally, the company has debuted new instruments and sutures within the last six months.
“This milestone reflects continued momentum for REMIND as we explore the potential of microrobotic surgical intervention to reshape the treatment of Alzheimer’s disease for the millions of people and their families impacted by this debilitating disease,” said Mark Toland, CEO of MMI.
